Biopharmaceuticals
AVI BioPharma Receives Department of Defense Contract for NEUGENE Program in Dengue Virus
Published in Gene Therapy Weekly, October 4th, 2007
AVI BioPharma, Inc. (Nasdaq:AVII) announced receipt of a $2.66 million contract for development of a therapeutic NEUGENE(R) antisense drug targeting dengue virus infections. This is the fourth contract related to an $11 million allocation for defense-related development of therapeutic antisense drugs, part of the 2006 Defense Appropriations Act. Under the four contracts, AVI anticipates receiving up to $9.8 million, net of government administrative costs.
In May 2007, AVI announced that it had received the first three signed contracts valued at approximately $7.1 million from the Department of Defense (DoD) for the development of therapeutic drugs targeting Ebola virus...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2007-10-04)
More Articles from Gene Therapy Weekly
- Cancer Gene Therapy
Novel Program Underway to Increase Participation in Clinical Trials - Cancer Gene Therapy
T vs. B: Re-engineered Human T Cells Effectively Target and Kill Cancerous B Cells - Gaucher Disease
Study Examines Implications of Genetic Screening for Certain Disease That Can Be Less Serious, Treatable - Gene Therapy
Mechanism for the in-vivo transport of siRNA - Mathematical Modeling
Scientists synthesize memory in yeast cells - Female Sexual Dysfunction
Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD) - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
